- Home
- FEMY vs LVTX Comparison
FEMY vs LVTX Comparison
Compare FEMY & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- LVTX
- Stock Information
- Founded
- FEMY 2004
- LVTX 2016
- Country
- FEMY United States
- LVTX Netherlands
- Employees
- FEMY N/A
- LVTX N/A
- Industry
- FEMY Medical/Dental Instruments
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- LVTX Health Care
- Exchange
- FEMY Nasdaq
- LVTX Nasdaq
- Market Cap
- FEMY 25.0M
- LVTX 27.9M
- IPO Year
- FEMY 2021
- LVTX 2021
- Fundamental
- Price
- FEMY $1.14
- LVTX $0.94
- Analyst Decision
- FEMY Strong Buy
- LVTX Buy
- Analyst Count
- FEMY 3
- LVTX 3
- Target Price
- FEMY $10.00
- LVTX $3.33
- AVG Volume (30 Days)
- FEMY 105.5K
- LVTX 119.3K
- Earning Date
- FEMY 11-12-2024
- LVTX 12-10-2024
- Dividend Yield
- FEMY N/A
- LVTX N/A
- EPS Growth
- FEMY N/A
- LVTX N/A
- EPS
- FEMY N/A
- LVTX N/A
- Revenue
- FEMY $1,260,643.00
- LVTX $7,345,000.00
- Revenue This Year
- FEMY $157.75
- LVTX $16.68
- Revenue Next Year
- FEMY $254.07
- LVTX N/A
- P/E Ratio
- FEMY N/A
- LVTX N/A
- Revenue Growth
- FEMY 15.33
- LVTX N/A
- 52 Week Low
- FEMY $0.73
- LVTX $0.88
- 52 Week High
- FEMY $2.40
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- FEMY 54.27
- LVTX 34.42
- Support Level
- FEMY $1.05
- LVTX $0.91
- Resistance Level
- FEMY $1.15
- LVTX $1.01
- Average True Range (ATR)
- FEMY 0.07
- LVTX 0.06
- MACD
- FEMY 0.01
- LVTX 0.02
- Stochastic Oscillator
- FEMY 58.82
- LVTX 15.05
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.